Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 747Carcinoma, Renal Cell 237Urinary Bladder Neoplasms 212Carcinoma, Transitional Cell 115Breast Neoplasms 100Kidney Neoplasms 97Neoplasms 91Carcinoma, Non-Small-Cell Lung 86Melanoma 82Ovarian Neoplasms 81Colorectal Neoplasms 76Neoplasm Metastasis 69Non-Muscle Invasive Bladder Neoplasms 58Lung Neoplasms 58Pancreatic Neoplasms 49Endometrial Neoplasms 46Sarcoma 43Stomach Neoplasms 42Uterine Cervical Neoplasms 41Carcinoma, Hepatocellular 36Adenocarcinoma 35Wilms Tumor 33Esophageal Neoplasms 33Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 29Testicular Neoplasms 25Metastatic Castration-resistant Prostate Cancer 25Disease 24Colonic Neoplasms 24

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × Genitourinary × 90 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡